A bone marrow transplant can buy time for people with aggressive B-cell cancers. Too often, it does not buy enough. For ...

CAR T-cell therapy has transformed the treatment of hematologic malignancies, yet many patients do not achieve lasting ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Your blood is constantly renewed by a hidden army—hematopoietic stem cells in your bone marrow. These cells can create every type of blood cell, but new research shows some are surprisingly picky, ...

In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

Study in adults and children with aplastic anemia identifies parallel evolutionary pathways used by hematopoietic stem cells ...